✦ LIBER ✦

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test

✍ Scribed by T. Kanda; F. Imazeki; Y. Yonemitsu; S. Mikami; N. Takada; T. Nishino; M. Takashi; A. Tsubota; K. Kato; N. Sugiura; A. Tawada; S. Wu; T. Tanaka; S. Nakamoto; R. Mikata; M. Tada; T. Chiba; T. Kurihara; M. Arai; K. Fujiwara; F. Kanai; O. Yokosuka

Book ID: 108886551
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 150 KB
Volume: 18
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2010.01409.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of insulin resistance with met

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

✍ Manuel Romero-Gómez; Moisés Diago; Raúl J. Andrade; José L. Calleja; Javier Salm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 1 views

Insulin resistance affects sustained virological response (SVR) in chronic hepatitis C. To know whether adding metformin to standard antiviral treatment improves SVR, we conducted a prospective, multicentered, randomized, double-blinded, placebo-controlled trial in 19 Spanish hospitals, including 12

Predicting sustained virological respons

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin

✍ Eric Snoeck; Janet R. Wade; Frank Duff; Matthew Lamb; Karin Jorga 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

Prediction of response to peginterferon-

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

✍ Yoshimasa Hashimoto; Hidenori Ochi; Hiromi Abe; Yasufumi Hayashida; Masataka Tsu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 1 views

## Abstract Variation at the IL‐28B locus was recently reported to be a significant predictive factor of viral response to pegylated‐interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL‐28B polymorphism rs8099917 and v

Efficacy and tolerability of peginterfer

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

✍ T. Witthoeft; D. Hueppe; C. John; J. Goelz; R. Heyne; B. Moeller; G. Teuber; S. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Efficacy and safety of peginterferon alf

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis

Clinical usefulness of total hepatitis C

Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin

✍ V. González; E. Padilla; M. Diago; M. D. Giménez; R. Solà; L. Matas; S. Montoliu 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB